Navigation Links
Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
Date:11/24/2013

SAN DIEGO, Nov. 24, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce results of the Light Study interim analysis on Monday, November 25, 2013 prior to market open. Following the announcement, Orexigen management will host a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).

The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 36202424. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application had been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com

McDavid Stilwell
Vice President, Corporate Communications & Business Development
858-875-8600


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
2. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
3. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
4. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
5. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
6. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
7. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
8. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
9. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
10. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
11. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016   BIOTRONIK will be ... care beyond the implant at the Heart Rhythm Society,s ... San Francisco . ... highest quality of patient care and satisfaction possible. Part ... each and every tomorrow," said Marlou Janssen , ...
(Date:5/3/2016)... , May 3, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... by Field Strength (High Field, Very High Field, Low ... (Brain, Head and Neck, Spine, Musculoskeletal, Vascular, Breast, Pelvic ... global magnetic resonance imaging (MRI) market was valued at ...
(Date:5/3/2016)... , May 3, 2016  Forté Elements, LLC (Forté) is excited to announce the ... that address the nutritional needs of recovery for a variety of clinical conditions. Founded ... Photo - http://photos.prnewswire.com/prnh/20160502/362548 Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Recognizing that lifestyle medicine is essential to health ... have tapped David Katz, MD, MPH, president of the American College of Lifestyle Medicine, ... medicine is especially gratifying,” said Katz. “There is so much opportunity to add years ...
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... ... recently partnered with local company MitoXcell in preparation of the launch of her new ... jump start plan is a nutritional guide designed to jump start a new healthy ...
(Date:5/4/2016)... ... May 04, 2016 , ... The preeminent surgical aftercare facility Pearl Recovery ... breast cancer surgery. In March 2016, the 61-year-old model and reality TV star was ... occurs in the milk ducts, according to an interview with the Daily Mail ...
(Date:5/4/2016)... ... May 04, 2016 , ... Advanced Spine & Sport ... restore its patients’ health, is hosting a free seminar on stem cell injections. The ... at Advanced Spine & Sport, 4601 Telephone Road, Suite 110, Ventura, CA. There are ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... ankles, and elbows. Engineered with athletes in mind, OMNIFORCE offers high-performance, less ... ineffective circular knitting, common in the industry) produces premium flat-knit construction with ...
Breaking Medicine News(10 mins):